Article

Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test.

Laboratoire de Virologie Moléculaire du centre de Recherche, Département de Microbiologie et Infectiologie, Hôpital Notre-Dame du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Journal of Clinical Microbiology (Impact Factor: 4.07). 06/2006; 44(6):1998-2006. DOI: 10.1128/JCM.00104-06
Source: PubMed

ABSTRACT The Roche PGMY primer-based research prototype line blot assay (PGMY-LB) is a convenient tool in epidemiological studies for the detection and typing of human papillomavirus (HPV) DNA. This assay has been optimized and is being commercialized as the Linear Array HPV genotyping test (LA-HPV). We assessed the agreement between LA-HPV and PGMY-LB for detection and typing of 37 HPV genotypes in 528 anogenital samples (236 anal, 146 physician-collected cervical, and 146 self-collected cervicovaginal swabs) obtained from human immunodeficiency virus-seropositive individuals (236 men and 146 women). HPV DNA was detected in 433 (82.0%) and 458 (86.7%) samples with PGMY-LB and LA-HPV (P = 0.047), respectively, for an excellent agreement of 93.8% (kappa = 0.76). Of the 17,094 HPV typing results, 16,562 (1,743 positive and 14,819 negative results) were concordant between tests (agreement = 96.9%; kappa = 0.76). The mean agreement between tests for each type was 96.4% +/- 2.4% (95% confidence interval [CI], 95.6% to 97.2%; range, 86% to 100%), for an excellent mean kappa value of 0.85 +/- 0.10 (95% CI, 0.82 to 0.87). However, detection rates for most HPV types were greater with LA-HPV. The mean number of types per sample detected by LA-HPV (4.2 +/- 3.4; 95% CI, 3.9 to 4.5; median, 3.0) was greater than that for PGMY-LB (3.4 +/- 3.0; 95% CI, 3.1 to 3.6; median, 2.0) (P < 0.001). The number of types detected in excess by LA-HPV in anal samples correlated with the number of types per sample (r = 0.49 +/- 0.06; P = 0.001) but not with patient age (r = 0.03 +/- 0.06; P = 0.57), CD4 cell counts (r = 0.06 +/- 0.06; P = 0.13), or the grade of anal disease (r = -0.11 +/- 0.06; P = 0.07). LA-HPV compared favorably with PGMY-LB but yielded higher detection rates for newer and well-known HPV types.

0 Bookmarks
 · 
86 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV-seropositive men having sex with other men (MSM) are at increased risk for anal Human Papillomavirus (HPV) infection, anal intraepithelial neoplasia (AIN) and anal cancer. Because most studies on the subject were cross-sectional, longitudinal investigations were needed to improve our understanding of anal carcinogenesis. Objective: To explore the longitudinal dynamics of anal HPV infection and predictors of progression to AIN 2/3 in HIV-infected MSM. Methods: Data from a prospective cohort of HIV-infected MSM in Montreal (the HIPVIRG cohort) were analysed for this thesis. Results: Incidence and clearance rates of anal HPV infection were calculated for each HPV type. The strongest predictor of progression to AIN 2/3 was a low nadir CD4 counts. We also found that a longer time on highly active antiretroviral therapy (HAART) was protective against progression. Conclusion: Results from this thesis contributes important knowledge to research of anal HPV and AIN. Les hommes infectés par le VIH ayant des relations avec des hommes (HARSAH) ont un risque accru d'être infectés par le virus du papillome humain (VPH) au niveau anal et de développer une néoplasie intra épithéliale (AIN) ou un cancer anal. Puisque la majorité des études publiées sur le sujet étaient transversales, des études longitudinales étaient désirées. Objectif : Explorer la dynamique longitudinale de l'infection anale par le VPH et identifier des prédicteurs de la progression vers des lésions AIN de haut-grade. Méthodes: Les données d'une étude de cohorte prospective chez des HARSAH infectés par le VIH (la cohorte HIPVIRG) ont été analysées pour ce mémoire. Résultats: Les taux d'incidence et de clairance du VPH anal ont été calculés pour chaque type de VPH. Un nadir de CD4 très bas a été identifié comme un prédicteur de progression vers un AIN 2 ou 3 alors que la durée de prise des antirétroviraux est protectrice. Conclusion: Les résultats de ce mémoire contribuent des apports de connaissances importants dans la recherche sur le VPH et les lésions AIN.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cervical cancer, the third most common cancer that affects women worldwide, is caused by the human papillomavirus (HPV) and is treatable when detected at an early stage. To date, more than 100 different HPV types have been described, and the development of simple, low-cost, and accurate methods to distinguish HPV genotypes is highly warranted. In this study, an HPV genotyping assay based on polymerase chain reaction (PCR) was evaluated. This method involved the use of MY09/11 primers followed by restriction fragment length polymorphism (RFLP) analysis with the restriction enzymes HpyCH4V and NlaIII. Cervical specimens preserved using CytoRich Blue fluid were collected from 1,134 female volunteers for HPV detection, and 1,111 valid samples were amplified using PCR. The PCR method was sensitive enough to detect 25 copies of HPV18, and three copies of HPV16. Out of 202 PCR-positive samples, HPV genotypes were determined in 189 samples (93.6%) by this RFLP method. Results were then evaluated further by capillary sequencing method. Concordant results between the two tests were as high as 96.0%. Thirteen samples, which tested negative with RFLP, were verified as non-specific amplifications with PCR. In conclusion, this PCR-RFLP method using restriction enzymes HpyCH4V and NlaIII is simple, non-labor intensive, and is applicable for the inexpensive determination of HPV genotypes in clinical samples. J. Med. Virol. 85:1229-1234, 2013. © 2013 Wiley Periodicals, Inc.
    Journal of Medical Virology 07/2013; 85(7):1229-34. · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human papillomaviruses (HPVs) have been recognized as etiologic factors in cervical carcinoma and several other anogenital cancers in females and males. HPV are classified as low risk (LR), probable high risk and high risk (HR) on the basis of their oncogenic potential. HPV genotypes, which are crucial for diagnosis and relationship with carcinogenesis, have been determined by several genotyping methods. In this study, two genotyping methods were compared: direct sequencing and INNO-LiPA. In total, 2,494 cervical specimens were tested and 27.2 % of these were found to be HPV DNA positive with 24.5% showing normal cytology. Specimens were divided into four groups according to their pathological cytology as normal, LSIL, HSIL and cancer and 134 specimens were selected for HPV genotyping by both methods. HPV genotyping results showed 87.5% positive correlation. With 17 specimens, the results were discordant, 12 specimens showed different genotypes. Others had genotypes that could not be typed by the INNO-LiPA method. Neither did direct sequencing in 3 different regions yield unequivocal results. Both genotyping methods have advantages and disadvantages. Consequently, the method most suitable for the study objective, budget and predominance of HPV genotype in any given area should be selected.
    Asian Pacific journal of cancer prevention: APJCP 01/2011; 12(4):989-94. · 1.50 Impact Factor

Full-text (2 Sources)

View
13 Downloads
Available from
May 28, 2014